Clinical usefulness of anaerobic blood culture in pediatric patients with bacteremia
CONCLUSION: Because many facultative anaerobic bacteria are recognized primarily from anaerobic blood culture bottles, combining aerobic and anaerobic blood culture bottles might be beneficial in pediatric patients with suspected blood stream infection.PMID:37993055 | DOI:10.1016/j.anaerobe.2023.102804 (Source: Anaerobe)
Source: Anaerobe - November 22, 2023 Category: Microbiology Authors: Ga Young Noh Yoon Soo Park Si Hyun Kim Sae Am Song Jeong Hwan Shin Source Type: research
Clinical usefulness of anaerobic blood culture in pediatric patients with bacteremia
CONCLUSION: Because many facultative anaerobic bacteria are recognized primarily from anaerobic blood culture bottles, combining aerobic and anaerobic blood culture bottles might be beneficial in pediatric patients with suspected blood stream infection.PMID:37993055 | DOI:10.1016/j.anaerobe.2023.102804 (Source: Anaerobe)
Source: Anaerobe - November 22, 2023 Category: Microbiology Authors: Ga Young Noh Yoon Soo Park Si Hyun Kim Sae Am Song Jeong Hwan Shin Source Type: research
Clinical usefulness of anaerobic blood culture in pediatric patients with bacteremia
CONCLUSION: Because many facultative anaerobic bacteria are recognized primarily from anaerobic blood culture bottles, combining aerobic and anaerobic blood culture bottles might be beneficial in pediatric patients with suspected blood stream infection.PMID:37993055 | DOI:10.1016/j.anaerobe.2023.102804 (Source: Anaerobe)
Source: Anaerobe - November 22, 2023 Category: Microbiology Authors: Ga Young Noh Yoon Soo Park Si Hyun Kim Sae Am Song Jeong Hwan Shin Source Type: research
Antimicrobial susceptibility testing of anaerobic bacteria causing bacteremia: A 13-year (2010-2022) retrospective study in a tertiary hospital
Anaerobe. 2023 Nov 19;84:102803. doi: 10.1016/j.anaerobe.2023.102803. Online ahead of print.ABSTRACTInfections from anaerobic microorganisms result from breached mucosal barriers, posing a significant mortality risk. A retrospective study at Hospital Universitario La Paz (Madrid) from 2010 to 2022 analyzed 491 (6.17 %) anaerobic bacteremia cases out of 7956 significant bacteremia cases among 171,833 blood culture requests. Bacteroides fragilis was the most frequently isolated species (28.3 %), followed by Clostridium perfringens (13.6 %). B. fragilis showed good susceptibility to amoxicillin/ clavulanic acid (86 %), pipera...
Source: Anaerobe - November 20, 2023 Category: Microbiology Authors: Jorge Ligero-L ópez Eduardo Rubio-Mora Mario David Ruiz-Basti án Mar ía Inmaculada Quiles-Melero Juana Cacho-Calvo Emilio Cendejas-Bueno Source Type: research
Antimicrobial susceptibility testing of anaerobic bacteria causing bacteremia: A 13-year (2010-2022) retrospective study in a tertiary hospital
Anaerobe. 2023 Nov 18:102803. doi: 10.1016/j.anaerobe.2023.102803. Online ahead of print.ABSTRACTInfections from anaerobic microorganisms result from breached mucosal barriers, posing a significant mortality risk. A retrospective study at Hospital Universitario La Paz (Madrid) from 2010 to 2022 analyzed 491 (6.17 %) anaerobic bacteremia cases out of 7956 significant bacteremia cases among 171,833 blood culture requests. Bacteroides fragilis was the most frequently isolated species (28.3 %), followed by Clostridium perfringens (13.6 %). B. fragilis showed good susceptibility to amoxicillin/clavulanate (86 %), piperacillin/t...
Source: Anaerobe - November 20, 2023 Category: Microbiology Authors: Jorge Ligero-L ópez Eduardo Rubio-Mora Mario David Ruiz-Basti án Mar ía Inmaculada Quiles-Melero Juana Cacho-Calvo Emilio Cendejas-Bueno Source Type: research
Antimicrobial susceptibility testing of anaerobic bacteria causing bacteremia: A 13-year (2010-2022) retrospective study in a tertiary hospital
Anaerobe. 2023 Nov 18:102803. doi: 10.1016/j.anaerobe.2023.102803. Online ahead of print.ABSTRACTInfections from anaerobic microorganisms result from breached mucosal barriers, posing a significant mortality risk. A retrospective study at Hospital Universitario La Paz (Madrid) from 2010 to 2022 analyzed 491 (6.17 %) anaerobic bacteremia cases out of 7956 significant bacteremia cases among 171,833 blood culture requests. Bacteroides fragilis was the most frequently isolated species (28.3 %), followed by Clostridium perfringens (13.6 %). B. fragilis showed good susceptibility to amoxicillin/clavulanate (86 %), piperacillin/t...
Source: Anaerobe - November 20, 2023 Category: Microbiology Authors: Jorge Ligero-L ópez Eduardo Rubio-Mora Mario David Ruiz-Basti án Mar ía Inmaculada Quiles-Melero Juana Cacho-Calvo Emilio Cendejas-Bueno Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4;84:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily N Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4;84:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily N Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Anaerobe. 2023 Nov 4:102788. doi: 10.1016/j.anaerobe.2023.102788. Online ahead of print.ABSTRACTAmong 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.PMID:37931679 | DOI:10.1016/j.anaerobe.2023.102788 (Source: Anaerobe)
Source: Anaerobe - November 6, 2023 Category: Microbiology Authors: Andrew M Skinner Xing Tan Colin Westman Thomas Birris Emily Drwiega Michael S Wang Stuart Johnson Source Type: research
